793PDPreliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. (23rd October 2018) - Abida, W; Bryce, A H; Vogelzang, N J; Amato, R J; Percent, I; Shapiro, J D; McDermott, R; Hussain, A; Patnaik, A; Petrylak, D; Ryan, C J; Stanton, T; et al.